Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia. We conducted a statistical analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) and the Canada Vigilance Adverse Reaction Database (CVARD) concerning the side effects of cholinesterase inhibitors. The statistics calculated for each adverse event were the frequency and the reporting odds ratios (ROR). A total of 9877 and 2247 reports were extracted from the FAERS and CVARD databases, respectively. A disproportionately higher frequency of reports of death as an adverse event for rivastigmine, compared to the other acetylcholinesterase inhibiting drugs, was observed in both the FAERS (ROR = 3.42; CI95% = 2.94-3.98; P<0.0001) and CVARD (ROR = 3.67; CI95% = 1.92-7.00; P = 0.001) databases. While cholinesterase inhibitors remain to be an important therapeutic tool against Alzheimer's disease, the disproportionate prevalence of fatal outcomes with rivastigmine compared with alternatives should be taken into consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“The rates of increase are not uniform from one country to another and they are projected to increase by 300% in developing countries while 100% in developed countries, making dementia and AD an international challenge for the future [8][9].”
BackgroundEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
Szumilas, M. (2010) · PubMed · Cited by 1,136
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
Bar-On, P., Millard, C. B., Harel, M., Dvir, H., Enz, A., Sussman, J. L., & Silman, I. (2002) · Biochemistry · doi:10.1021/bi020016x · Cited by 328
Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease
Jann, M. W. (2000) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.1.1.34664 · Cited by 236 · cited 1×
“Rivastigmine, on the other hand, has been classified as an intermediate-acting agent (pseudo-irreversible) [30].”
BackgroundWinblad, B., Grossberg, G., Frölich, L., Farlow, M., Zechner, S., Nagel, J., & Lane, R. (2007) · Neurology · doi:10.1212/01.wnl.0000281847.17519.e0 · Cited by 136
Hoffman, K. B., Kraus, C., Dimbil, M., & Golomb, B. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042866 · Cited by 124 · cited 1×
“Indeed, ROR is generally used to evaluate disproportion in reporting AEs for a drug in comparison with all other drugs and it has been very useful for many pharmacovigilance studies [24].”
BackgroundThe pharmacology of donepezil: a new treatment for Alzheimer’s disease
Wilkinson, D. G. (1999) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.1.121 · Cited by 110
Huang, F., & Fu, Y. (2010) · Current Clinical Pharmacology · doi:10.2174/157488410791110805 · Cited by 58
Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease
Emre, M., Bernabei, R., Blesa, R., Bullock, R. A., Cunha, L., Daniëls, H., Dziadulewicz, E. K., Förstl, H., Frölich, L., Gabryelewicz, T., et al. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00141.x · Cited by 39
Chen, Y., Guo, J. J., Steinbuch, M., Lin, X. S., Buncher, C. R., & Patel, N. C. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256733 · Cited by 38 · cited 1×
“Among four widely used data mining algorithms, ROR showed the best performance for pharmacovigilance surveys [22][23].”
MethodA Fatal Outcome After Unintentional Overdosing of Rivastigmine Patches
Lövborg, H., Jönsson, A. K., & Hägg, S. (2012) · Current Drug Safety · doi:10.2174/157488612800492717 · Cited by 28 · cited 1×
“Indeed, a 2012 report from Henrik Lövborg, Anna K Jönsson and Staffan Hägg [26] illustrates a patient’s fatal outcome involving a rivastigmine overdose due to a medication error with the patch form.”
BackgroundHan, H. J., Lee, J. J., Park, S. A., Park, H. Y., Kim, J. E., Shim, Y. S., Shim, D.-S., Kim, E., Yoon, S. J., & Choi, S. H. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.3.137 · Cited by 24 · cited 1×
“Several controlled clinical trials based on a specially selected population have tested these three drugs and showed them to be of comparable efficacy and safety [10][11][12].”
BackgroundA Rare Case of Acute Renal Failure Secondary to Rhabdomyolysis Probably Induced by Donepezil
Şahin, O. Z., Ayaz, T., Yuce, S., Sümer, F., & Şahin, S. B. (2014) · Case Reports in Nephrology · doi:10.1155/2014/214359 · Cited by 8
Cited by
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Ding, Z., Leung, P.-Y., Lee, T.-L., & Chan, A. S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101886 · Cited by 31
Ojha, P. S., Biradar, P. R., Tubachi, S., & Patil, V. S. (2023) · Advances in Traditional Medicine · doi:10.1007/s13596-021-00627-x · Cited by 24
Auvelity as a Potential Treatment for Alzheimer’s Disease
Lepkowsky, C. M. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3206 · Cited by 2
Metadata
- Authors
- Ali, T. B., Schleret, T. R., Reilly, B. M., Chen, W. Y., & Abagyan, R.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-12-07
- Volume
- 10
- Issue
- 12
- Pages
- e0144337
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2192171349
- Cited by
- 179
- References
- 18
- FWCI
- 19.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.